Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 986-990

  Le, T ^a,c   Shahriari, P ^a   Hopkins, L ^a   Faught, W ^b   Fung Kee Fung, M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Neoadjuvant chemotherapy; Prognosis; Tumor necrosis

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE COURSE; FEMALE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CA-125 ANTIGEN; CARBOPLATIN; CARCINOMA; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NECROSIS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SECOND-LOOK SURGERY; SURVIVAL RATE;

EID: 33745070839     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00594.x     Document Type: Article

References (29)

1. Barnholtz-Sloan JS Schwartz AG Qureshi F Jacques S Malone J Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003 189 : 1120 7.
2. McGuire V Jesser CA Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002 84 : 399 403.
3. Schink JC. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 1999 26 ( 1 Suppl. 1 2 7.
4. Omura GA Brady MF Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Orthod 1991 9 : 1138 50.
5. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993 71 ( Suppl. 4 1534 40.
6. Chi DS Franklin CC Levine DA et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004 94 : 650 4.
7. Crawford SC Vasey PA Paul J Hay A Davis JA Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Orthod 2005 23 : 8802 11.
8. Aletti GD Gostout BS Podratz KC Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006 100 : 33 7.
9. Chen SS Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 1985 20 : 190 5.
10. Brown JV Karlan BY Greenspoon JS. Perioperative coagulopathy in patients undergoing primary cytoreduction. Cancer 1993 71 : 2557 61.
11. Bachsbaum HJ Brady MF Delgado G et al. Surgical staging of ovarian carcinoma: stage I, II, and III: a Gynecologic Oncology Group study. Surg Gynecol Obstet 1989 162 : 226 9.
12. Sharma S Driscoll D Odunsi K Venkatadri A Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol 2005 193 : 2077 82.
13. Pecorelli S Odicino F Favalli G. Interval debulking surgery in advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynecol 2002 : 16 : 573 83.
14. Vergote IB De Wever I Decloedt J et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000 27 ( 3 Suppl. 7 31 6.
15. Loizzi V Cormio G Resta L et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int J Gynecol Cancer 2005 15 : 217 23.
16. Pu RT Schott AF Sturtz DE Griffith KA Kleer CG. Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 2005 29 : 354 8.
17. Quintana J Beresi V DelPozo H et al. Intra-arterial cisplatin given prior to surgery in osteosarcoma: grade of necrosis and size of tumor as major prognostic factors. Am J Pediatr Hematol Oncol 1991 13 : 269 73.
18. Eilber FC Rosen G Eckardt J et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Orthod 2001 19 : 3203 9.
19. Kesler KA Rieger KM Ganjoo KN et al. Primary mediastinal nonseminomatous germ cell tumors: the influence of postchemotherapy pathology on long-term survival after surgery. J Thorac Cardiovasc Surg 1999 118 : 692 700.
20. Vrscaj MU Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 2002 23 : 405 10.
21. Ushijima K Ota S Komai K et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg 2002 87 : 185 90.
22. Kayikcioglu F Kose MF Boran N Caliskan E Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Cancer 2001 11 : 466 70.
23. Leek RD Landers RJ Harris AL Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999 79 : 991 5.
24. Gilchrist KW Gray R Fowble B Tormey DC Taylor SG. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Orthod 1993 11 : 1929 35.
25. Bjornsson J Inwards CY Wold LE Sim FH Taylor WF. Prognostic significance of spontaneous tumour necrosis in osteosarcoma. Virchows Arch A Pathol Anat Histopathol 1993 423 : 195 9.
26. Penault-Llorca F Levrel O Clemenson A et al. Assessment of different histoprognosis grading systems for primary ovarian cancer: 100 patients given the same treatment for primary ovarian adenocarcinoma. J Gynecol Obstet Biol Reprod (Paris) 2000 29 : 548 54.
27. Green JA Duffaud F Coens C et al. Prognostic value of clinical and molecular markers in advanced ovarian cancer (AOC): importance of residual (Rs) disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 phase III randomized clinical trial (RCT) [abstract]. J Clin Oncol 2005 165 : 456.
28. Menendez LR Fideler BM Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg Am 1993 75 : 526 31.
29. Schulte M Brecht-Krauss D Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999 40 : 1637 43.